Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service peripheral nerve stimulation & intrathecal pumps cases in California: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 11% on average (174 state-years, 2020–2024): read it as a direction with a margin.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 26 | 1,864 | 48% |
| 2020 | 26 | 1,661 | 50% |
| 2021 | 24 | 1,825 | 52% |
| 2022 | 29 | 1,889 | 53% |
| 2023 | 39 | 2,564 | 55% |
| 2024 | 35 | 2,932 | 56% |
| 2025 from claims | – | 3,951 3,626–4,181 | 56% |
| 2026 forecast | – | 4,357 3,834–5,028 | 56% |
| 2027 forecast | – | 4,780 4,087–5,697 | 56% |
| 2028 forecast | – | 5,244 4,376–6,421 | 56% |
| 2029 forecast | – | 5,753 4,699–7,215 | 57% |
| 2030 forecast | – | 6,311 5,056–8,087 | 57% |
PNS lead and generator, intrathecal pump and catheter. Professional codes (what the surgeon bills): CPT 64555, 64590, 62362, 62350.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 55% of the cases CMS names in California; 20 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2025, 1% inpatient hospital, 21% hospital outpatient, 74% surgery center, 4% office. The share outside the hospital has moved +20 pts since 2019, so more of this market is decided in surgery centers and offices each year.
| Forecast, Medicare FFS | Inpatient | Hospital outpatient | Surgery center | Office |
|---|---|---|---|---|
| 2026 · ~4,400 | ~61 | ~810 | ~3,300 | ~160 |
| 2027 · ~4,800 | ~68 | ~830 | ~3,700 | ~170 |
| 2028 · ~5,200 | ~74 | ~880 | ~4,100 | ~180 |
The forecast’s cases at the projected mix.
If the trend since 2022 holds, slowing as it goes, by 2028: surgery center about 78% (74% in 2025), hospital outpatient about 17% (21% in 2025). More of these cases each year are decided in surgery centers, where the surgeons often own the center and weigh price and turnaround.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| Arizona | 23 | 1,632+19%/yr | +19%/yr | 2.0 | 90% | 3,070 in 2030+11%/yr |
| Washington | 8 | 573+7.4%/yr | +7.4%/yr | 0.7 | 55% | 1,090 in 2030+11%/yr |
| Colorado | 10 | 515+13%/yr | +13%/yr | 1.0 | 55% | 1,080 in 2030+13%/yr |
| Idaho | 4 | 403+11%/yr | +11%/yr | 1.8 | 20% | 790 in 2030+12%/yr |
| Oregon | 4 | 325+4.4%/yr | +4.4%/yr | 0.7 | 91% | 1,740 in 2030+32%/yr |
| Nevada | 2 | 316−0.6%/yr | −0.6%/yr | 1.0 | 71% | 550 in 2030+9.6%/yr |
| Utah | 1 | 290+14%/yr | +14%/yr | 1.2 | 60% | 570 in 2030+12%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Radiofrequency ablation (facet, genicular, basivertebral) | 375 | 24,956+2.5%/yr | +2.5%/yr | 7.10.6× | 86% | 32,700 in 2030+4.6%/yr |
| Spinal cord & DRG stimulation | 48 | 1,564−4.8%/yr | −4.8%/yr | 0.40.6× | 89% | 1,890 in 2030+3.2%/yr |
Peripheral nerve stimulation & intrathecal pumps in every state, and its device makers · Every procedure market in California · Every state · Compare with Arizona
Spr Therapeutics leads with 32% of company spending on these surgeons in 2025, level with 2024.
In 2025, 11 companies reported engagement with California’s surgeons worth $635K in consulting, speaking, meals and travel tied to these products, about $18K per surgeon billing it. Royalties are left out.
FDA, last 12 months: 13 clearances and approvals in the category, 2 recalled product lines. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.